FY2025 · ended Dec 28, 2025 · Revenue $2.86B, +3.7% YoY · Filed Feb 24, 2026
Revvity, Inc (RVTY) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In fiscal 2025, which ended Dec 28, 2025, it reported revenue of $2.9 billion and net income of $241.2 million. Free cash flow was $509.4 million. As of Jul 5, 2026 it held $1.0 billion in cash and investments and $3.4 billion in total debt.
Revenue (TTM)
$2.91B
+4.1% vs year-ago TTM
Net income (TTM)
$237.55M
-16.7% vs year-ago TTM
Operating cash flow (TTM)
$627.63M
+7.4% vs year-ago TTM
Free cash flow (TTM)
$558.11M
+11.0% vs year-ago TTM
EPS (TTM)
$2.10
-11.2% vs year-ago TTM
Dividend per share
$0.28
+0.0% vs prior year
Shares outstanding
111.80M
-7.0% vs prior year
Net cash
$-2.34B
as of Jul 5, 2026
Operating margin
12.3%
FY 2026
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- RVTY (NYSE)
- Fiscal year ends
- December 29
- Incorporated in
- MA
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 31791
- Former names
- PERKINELMER INC (until Apr 14, 2023); EG&G INC (until Jul 26, 1999)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
- 10x Genomics, Inc. TXG
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 28, 2025 |
FY 2024 Dec 29, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Jan 1, 2023 |
FY 2021 Jan 2, 2022 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $2.8B | $2.8B | $3.3B | $3.8B |
| Operating income | $356.6M | $346.7M | $300.6M | $742.7M | $1.3B |
| Net income | $241.2M | $270.4M | $693.1M | $569.2M | $943.2M |
| Diluted EPS | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 |
| Operating cash flow | $582.9M | $628.3M | $91.3M | $679.8M | $1.4B |
| Free cash flow | $509.4M | $541.7M | $9.9M | $594.2M | $1.3B |
| Total assets | $12.2B | $12.4B | $13.6B | $14.1B | $15.0B |
| Total liabilities | $4.9B | $4.7B | $5.7B | $6.7B | $7.9B |
| Stockholders' equity | $7.3B | $7.7B | $7.9B | $7.4B | $7.1B |
| Cash and investments | $947.8M | $1.2B | $1.6B | $465.4M | $637.0M |
| Total debt | $3.4B | $3.3B | $4.1B | $4.6B | $5.2B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jul 5, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 4, 2026 | Aug 4, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Apr 5, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
May 5, 2026 | May 5, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 1, 2026 | Apr 28, 2026 |
All 1000 Revvity, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.